
    
      Patients with locally advanced breast cancer and patients with metastatic breast cancer who
      have not previously received an anthracycline will be treated with docetaxel and epirubicin.

      Patients with metastatic breast cancer who have already received anthracyclines will be
      treated with docetaxel and capecitabine.

      All patients will be randomized to receive their treatment either on an every three week
      schedule, or on a weekly schedule.
    
  